Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line
Yıl: 2019 Cilt: 44 Sayı: 1 Sayfa Aralığı: 78 - 85 Metin Dili: İngilizce DOI: 10.1515/tjb-2018-0099 İndeks Tarihi: 06-06-2020
Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line
Öz: Objective: Investigation of the anticarcinogenic effects of natural products with low toxicity is very important in the development of new therapeutic strategies against cancer. Ginnalin A (GA) is one of the most important phenolic compounds of Acer genus and its anticancer effect has been shown that in various cancer cell lines. SB203580, a p38 MAPK inhibitor, can inhibit cell proliferation independently of p38 MAPK. The objective of this study was to investigate combination effect of GA and SB203580 on Hep-3B cell line. Material and methods: Cell viability was determined by using XTT method after the treatment with GA, SB203580 and combination of both. Anticarcinogenic effects of GA and SB203580 both in single and in combination have been analyzed with Caspase-3 activity assay and expression levels of important genes involved in cell cycle and apoptosis were evaluated by qPCR. Results: GA and SB203580 have shown additive effect on Hep-3B cells in the combination inhibited 50% of cell viability. And, SB203580 increased the effect of GA on activation of Caspase-3 and expressions of genes important in apoptosis and cell cycle. Conclusion: This study indicates that GA and SB203580 can be an effective for development of new therapeutic strategies in hepatocellular carcinoma.
Anahtar Kelime: Ginnalin A ve SB203580 Hep-3B hepatosellüler karsinoma hücre hattında additif etki gösterir
Öz: Amaç: Düşük toksisiteli doğal ürünlerin antikarsinojenik etkilerinin araştırılması, kansere karşı yeni tedavi stratejilerinin geliştirilmesinde oldukça önemlidir. Ginnalin A (GA), Acer cinsinin en önemli fenolik bileşiklerinden biridir ve çeşitli kanser hücre hatlarında antikanser etkisi gösterilmiştir. Bir p38 MAPK inhibitörü olan SB203580, p38 MAPK’den bağımsız olarak hücre proliferasyonunu inhibe edebilmektedir. Bu çalışmanın amacı, GA ve SB203580’in Hep-3B hücre hattında kombinasyon etkisinin araştırılmasıdır. Yöntem: GA, SB203580 ve her ikisinin kombinasyonu ile muameleden sonra hücre canlılığı XTT yöntemi kullanılarak belirlenmiştir. GA ve SB203580’in hem tek başına hem de kombine olarak antikarsinojenik etkileri Kaspaz-3 aktivite testi ile analiz edilmiş ve hücre döngüsü ile apoptozda önemli genlerin ekspresyon seviyeleri qPCR ile değerlendirilmiştir. Bulgular: GA ve SB203580, Hep-3B hücreleri üzerinde hücre canlılığının %50’sini inhibe ettikleri kombinasyonda additif etki göstermiştir. Ayrıca, SB203580 GA’nın Kaspaz-3 aktivasyonu ve apoptoz ile hücre döngüsünde önemli olan genlerin ifadeleri üzerindeki etkisini arttırmıştır. Sonuç: Bu çalışma, GA ve SB203580’in hepatosellüler karsinomada yeni terapötik stratejilerin geliştirilmesinde etkili olabileceğini göstermektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Tam K. The roles of doxorubicin in hepatocellular carcinoma. ADMET & DMPK 2003;1:29–44.
- 2. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver 2016;10:332–9.
- 3. Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, et al. Risk factors of hepatocellular carcinoma—current status and perspectives. Asian Pac J Cancer Prev 2012;13:743–52.
- 4. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1.
- 5. Chen C. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. Gut 2018;67:595–8.
- 6. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 2017;24:1073274817729245.
- 7. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115–27.
- 8. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) 2017;96:e5904.
- 9. Gwiasda J, Schulte A, Kaltenborn A, Ramackers W, Kleine M, Beetz O, et al. Identification of the resection severity index as a significant independent prognostic factor for early mortality and observed survival >5 and >10 years after liver resection for hepatocellular carcinoma. Surg Oncol 2017;26:178–87.
- 10. Deng G, Zeng S, Ma J, Zhang Y, Qu Y, Han Y, et al. The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma. Sci Rep 2017;7:41616.
- 11. Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol 2017;9:907–20.
- 12. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol 2018;48:103–14.
- 13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
- 14. Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett 2016;371:171–81.
- 15. Cai Y, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci 2004;74:2157–84.
- 16. Galati G, O’Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med 2004;37:287–303.
- 17. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer 2010;62:1–20.
- 18. Chung KT, Wong TY, Wei CI, Huang YW, Lin Y. Tannins and human health: a review. Crit Rev Food Sci Nutr 1998;38:421–64.
- 19. Park KH, Yoon KH, Yin J, Le TT, Ahn HS, Yoon SH, et al. Antioxidative and anti-inflammatory activities of galloyl derivatives and antidiabetic activities of Acer ginnala. Evid Based Complement Alternat Med 2017;2017:6945912.
- 20. Han SS, Lo SC, Choi YW, Kim JH, Baek SH. Antioxidant activity ofcrude extract and pure compounds of Acer ginnala Max. Bull Korean Chem Soc 2004;25:389–91.
- 21. Honma A, Koyama T, Yazawa K. Anti-hyperglycemic of sugar maple Acer saccharum and its constituent acertannin. Food Chem 2010;123:390–4.
- 22. González-Sarrías A, Li L, Seeram NP. Effects of maple (Acer) plant part extracts on proliferation, apoptosis and cell cycle arrest of human tumorigenic and non-tumorigenic colon cells. Phytother Res 2012;26:995–1002.
- 23. González-Sarrías A, Ma H, Edmonds ME, Seeram NP. Maple polyphenols, ginnalins A-C, induce S- and G2/M-cell cycle arrest in colon and breast cancer cells mediated by decreasing cyclins A and D1 levels. Food Chem 2013;136:636–42.
- 24. Zhang H, Chen GG, Zhang Z, Chun S, Leung BC, Lai PB. Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK. Apoptosis 2012;17:325–34.
- 25. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R. p38 Mitogenactivated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic druginduced mitotic arrest. Mol Biol Cell 2003;14:2071–87.
- 26. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010;429:403–17.
- 27. Lali FV, Hunt AE, Turner SJ, Foxwell BM. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 2000;275:7395–402.
- 28. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450–4.
- 29. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.
- 30. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225–35.
- 31. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
- 32. Alnajjar AM, Elsiesy HA. Natural products and hepatocellular carcinoma: a review. Hepatoma Res 2015;1:119–24.
- 33. Anantharaju PG, Gowda PC, Vimalambike MG, Madhunapantula SV. An overview on the role of dietary phenolics for the treatment of cancers. Nutr J 2016;15:99.
- 34. Stone JG, Siedlak SL, Tabaton M, Hirano A, Castellani RJ, Santocanale C, et al. The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol 2011; 70:578–87.
- 35. Baig S, Seevasant I, Mohamad J, Mukheem A, Huri HZ, Kamarul T. Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis 2016;7:e2058.
- 36. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342–8.
- 37. Nakamura H, Kumei Y, Morita S, Shimokawa H, Ohya K, Shinomiya K. Antagonism between apoptotic (Bax/Bcl-2) and anti-apoptotic (IAP) signals in human osteoblastic cells under vector-averaged gravity condition. Ann N Y Acad Sci 2003;1010:143–7.
- 38. Li F, Cao B, Ge JF, Zhao J, Jiang D, Zheng SY. Expression of caspase-3 gene in gastric adenocarcinoma cell line SGC-7901 via Ad-FasL. Int J Clin Exp Pathol 2016;9:357–62.
- 39. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 2008;9:115–28.
| APA | VURAL H, ÖZDEN P, Güçlü E (2019). Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. , 78 - 85. 10.1515/tjb-2018-0099 |
| Chicago | VURAL Hasibe,ÖZDEN Pınar,Güçlü Ebru Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. (2019): 78 - 85. 10.1515/tjb-2018-0099 |
| MLA | VURAL Hasibe,ÖZDEN Pınar,Güçlü Ebru Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. , 2019, ss.78 - 85. 10.1515/tjb-2018-0099 |
| AMA | VURAL H,ÖZDEN P,Güçlü E Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. . 2019; 78 - 85. 10.1515/tjb-2018-0099 |
| Vancouver | VURAL H,ÖZDEN P,Güçlü E Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. . 2019; 78 - 85. 10.1515/tjb-2018-0099 |
| IEEE | VURAL H,ÖZDEN P,Güçlü E "Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line." , ss.78 - 85, 2019. 10.1515/tjb-2018-0099 |
| ISNAD | VURAL, Hasibe vd. "Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line". (2019), 78-85. https://doi.org/10.1515/tjb-2018-0099 |
| APA | VURAL H, ÖZDEN P, Güçlü E (2019). Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. Türk Biyokimya Dergisi, 44(1), 78 - 85. 10.1515/tjb-2018-0099 |
| Chicago | VURAL Hasibe,ÖZDEN Pınar,Güçlü Ebru Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. Türk Biyokimya Dergisi 44, no.1 (2019): 78 - 85. 10.1515/tjb-2018-0099 |
| MLA | VURAL Hasibe,ÖZDEN Pınar,Güçlü Ebru Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. Türk Biyokimya Dergisi, vol.44, no.1, 2019, ss.78 - 85. 10.1515/tjb-2018-0099 |
| AMA | VURAL H,ÖZDEN P,Güçlü E Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. Türk Biyokimya Dergisi. 2019; 44(1): 78 - 85. 10.1515/tjb-2018-0099 |
| Vancouver | VURAL H,ÖZDEN P,Güçlü E Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line. Türk Biyokimya Dergisi. 2019; 44(1): 78 - 85. 10.1515/tjb-2018-0099 |
| IEEE | VURAL H,ÖZDEN P,Güçlü E "Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line." Türk Biyokimya Dergisi, 44, ss.78 - 85, 2019. 10.1515/tjb-2018-0099 |
| ISNAD | VURAL, Hasibe vd. "Ginnalin A and SB203580 show additive effect on Hep-3B hepatocellular carcinoma cell line". Türk Biyokimya Dergisi 44/1 (2019), 78-85. https://doi.org/10.1515/tjb-2018-0099 |
